Categories
World News

After wobbly liftoff, Astra House rocket fails to succeed in orbit as soon as once more

The rocket maker Astra Space launched its first rocket since the company’s IPO on Saturday. After a shaky launch, the rocket missed its target of reaching orbit.

As it lifted off, the missile appeared to be moving sideways rather than straight up. Chris Kemp, founder, chairman and CEO of Astra, told CNBC that an engine shut down about a second after the flight. The company is currently investigating the reason.

Astra founder and chief technology officer Adam London added that the system worked relatively well under the circumstances. Even with a failed engine, the missile had enough thrust to lift off the platform very slowly, and the guidance system kept control of the missile.

About 2 minutes and 28 seconds after the flight, the flight security crew issued an order to shut down all engines, which resulted in the missile stalling, the CEO said. It reached an altitude of about 50 kilometers and returned to Earth with no injury or property damage.

“It was obviously unsuccessful in getting anything into orbit, but it was a flight that taught us an incredible amount,” Kemp told CNBC. “We have a Series 7 that’s in production right now, and we’re going to take what we’ve learned here and put any changes into this rocket and be flying soon.”

“We have a tremendous amount of data from the flight and are in the process of reviewing it,” he added.

Executives declined to give a timetable for completing the investigation or building a new missile and the next flight.

Astra abandoned its first attempt at launch on Friday, with the rocket’s engines firing for a moment and then shutting down.

On Saturday, after a short break due to refueling problems, Astra launched the LV0006 rocket from the Pacific Spaceport Complex in Kodiak, Alaska at around 3:35 p.m. local time.

This was the first commercial launch for Astra, with the US Space Force hiring the launch to test a payload as part of their space test program.

The vehicle is 43 feet tall and fits in the small missile segment of the introductory market. Astra’s goal is to eventually launch as many of its small rockets as possible, with the goal of launching one rocket a day by 2025 and bringing the $ 2.5 million price tag even lower.

Saturday’s mission, postponed after Astra abandoned a launch attempt on Friday, tested a variety of upgrades to Astra’s rocket since its last mission in December. While that previous mission made it into space, the rocket ran out of fuel and only made it into orbit.

LV0006 on the launch pad in Kodiak, Alaska.

Astra

One of the company’s missiles had a problem with the guidance system during the company’s first mission early last year and crashed after launch.

Astra has teamed up with NASASpaceflight – a space industry content organization not affiliated with the US agency – to webcast the launch on Saturday.

This is a development story, please check back for updates.

Categories
World News

Child Born on Afghan Flight Is Named Attain, After Jet’s Name Signal

The Afghan parents of a baby born on a C-17 plane that was evacuating passengers to Germany named their daughter after the plane’s call sign, a senior US general said this week.

“They named the little girl Reach, and they did so because the callsign of the C-17 plane that flew them from Qatar to Ramstein was Reach,” said General Tod Wolters, commander of US European Command, in a Pentagon -Message conference on Wednesday.

The Afghan mother, who is not named, had contractions and complications on Saturday on a flight from a base in Qatar to the Ramstein air base in southwest Germany, the US Air Force said on Twitter.

In response, the C-17 – identified on the radio as Reach 828 – sank in altitude to increase air pressure on the plane, “which helped stabilize and save the mother’s life,” the Air Force said.

After the plane landed, paramedics got on board and helped drop the baby into the hold. A group of women protected their mother’s privacy with their scarves, said Capt. Erin Brymer, a nurse who helped deliver the child, told CNN.

By the time they got there, the woman was “past the point of no return,” she said. “This baby was supposed to be born before we could possibly move it to another facility.”

Pictures released by the US Air Force showed the woman being transported from the plane to a nearby medical facility shortly after the birth of her daughter.

General Wolters said the baby was one of three – all in good condition – born to women who boarded evacuation flights from Afghanistan. Two more were delivered at the Landstuhl Regional Medical Center, a military hospital in southern Germany.

“It is my dream to see this little kid named Reach grow up and become a US citizen and fly United States Air Force fighter jets in our air force,” General Wolters told reporters.

Categories
Health

Drug Distributors and J.&J. Attain $26 Billion Deal to Finish Opioids Lawsuits

After two years of wrangling, the country’s three major drug distributors and a pharmaceutical giant have reached a $26 billion deal with states that would release some of the biggest companies in the industry from all legal liability in the opioid epidemic, a decades-long public health crisis that has killed hundreds of thousands of Americans.

The announcement was made Wednesday afternoon by a bipartisan group of state attorneys general.

The offer will now go out to every state and municipality in the country for approval. If enough of them formally sign on to it, billions of dollars from the companies could begin to be released to help communities pay for addiction treatment and prevention services and other steep financial costs of the epidemic.

In return, the states and cities would drop thousands of lawsuits against the companies and pledge not to bring any future action.

The settlement binds only these four companies — the drug distributors Cardinal Health, AmerisourceBergen, McKesson, and Johnson & Johnson — leaving thousands of other lawsuits against many other pharmaceutical defendants, including manufacturers and drugstore chains, in the mammoth nationwide litigation still unresolved.

But these four companies are widely seen as among the defendants with the deepest pockets.

In an emailed statement, Michael Ullmann, executive vice president and general counsel of Johnson & Johnson, said: “We recognize the opioid crisis is a tremendously complex public health issue, and we have deep sympathy for everyone affected. This settlement will directly support state and local efforts to make meaningful progress in addressing the opioid crisis in the United States.”

In a joint statement, the three distributors said: “While the companies strongly dispute the allegations made in these lawsuits, they believe the proposed settlement agreement and settlement process it establishes are important steps toward achieving broad resolution of governmental opioid claims and delivering meaningful relief to communities across the United States.”

The distributors, which by law are supposed to monitor quantities of prescription drug shipments, have been accused of turning a blind eye for two decades while pharmacies across the country ordered millions of pills for their communities. Plaintiffs also allege that Johnson & Johnson, which used to contract with poppy growers in Tasmania to supply opioid materials to manufacturers and made its own fentanyl patches for pain patients, downplayed addictive properties to doctors as well as patients.

According to federal data, from 1999 to 2019, 500,000 people died from overdoses to prescription and street opioids. Overdose deaths from opioids hit a record high in 2020, the Centers for Disease Control and Prevention said earlier this month.

Under the agreement, the country’s three distributors would make payments over 18 years. Johnson & Johnson would pay $5 billion over nine years. A key feature of the agreement is that the distributors would establish an independent clearinghouse to track and report one another’s shipments, a new and unusual mechanism intended to make data transparent and send up red flags immediately when outsized orders are made.

A separate deal between the companies and Native American tribes is still being negotiated.

The agreement was presented by attorneys general from North Carolina, Pennsylvania, New York, Delaware, Louisiana, Tennessee and Connecticut.

Wednesday’s announcement suggests that a critical element — a large majority of states agreeing in principle — has been met. But there are daunting obstacles remaining before any checks are actually cut.

The states and the District of Columbia will now have 30 days to closely review the agreement, including how much each would be paid over 17 years. Many states have not yet had the chance to scrutinize the deal. And while many permit their attorneys general to sign off, others require that legislators must be consulted. An unspecified number of states must sign on, for the deal to proceed. If that threshold is not met, the companies could walk away.

While the states are deciding, a trial brought by several California counties in state court against Johnson & Johnson and a local West Virginia trial in federal court against the distributors will continue.

States also have to begin cajoling their localities, including those that have already filed cases and those that have not, to agree to the deal. The greater the number of local governments that sign on, the greater the amount of money each state will receive.

“The lawyers will do a lot of the strong-arming of their clients, the localities, into agreeing to the settlements, because if the deal doesn’t go through, the lawyers won’t get paid,” said Elizabeth Burch, a law professor at the University of Georgia who has followed the litigation closely.

Categories
Politics

Biden to rally Senate Democrats after they attain $3.5 trillion finances deal

President Joe Biden will meet with the Senate Democratic Senate on Wednesday to endorse support for its far-reaching infrastructure and business investment goals, hours after lawmakers announced it had reached an agreement on a multi-trillion dollar budget decision Has.

That budget arrangement, which would spend $ 3.5 trillion over the next decade, will be added to the roughly $ 600 billion in new spending included in a bipartisan infrastructure plan, Democrats said Tuesday evening.

They said the budget plan was paid in full and would expand Medicare coverage for dental, visual and hearing services – two features that could help attract moderate and progressive Democrats to endorse it.

Over a closed door caucus lunch in the Capitol on Wednesday, Biden will assemble the Democrats and “lead us to this wonderful plan,” Senate Majority Leader Chuck Schumer told DN.Y.

CNBC policy

Read more about CNBC’s political coverage:

White House press secretary Jen Psaki tweeted Wednesday morning that the president would “continue to advocate the duel-track approach to the economy by investing in infrastructure, protecting our climate and helping the next generation of workers and families better to rebuild ”.

She noted in a follow-up that she had misspelled the word “dual”.

Democratic leaders hope to get versions of the resolution through the House and Senate before lawmakers leave Washington for the August recess.

However, they admitted on Tuesday evening that their work for them was canceled because the budget only provides a rough overview of the expenses that would have to be specified in subsequent laws.

“We know that we have a long way to go,” said Schumer.

“I have no illusions how challenging this will be,” said Senator Mark Warner, D-Va., Vice chairman of the caucus.

The resolution, if passed, would pave the way for Democrats to pass a later Senate spending bill through what is known as the budget reconciliation process. That means that the Democrats would only need a simple majority in the Senate – which is 50:50 50:50 with the Republicans – and not the 60 votes that the GOP could demand through the filibuster rules.

If all 50 Democrats in the Senate support such a law, they could pass it without Republican support, as Democratic Vice President Kamala Harris could cast the decisive vote.

Senate Democratic leaders are working to get both the moderates in the faction, who have expressed their discomfort about funding the mammoth spending plans, and the progressives, who have called for much more money to spend.

Senator Bernie Sanders, on whom Schumer charged charges of including expanded Medicare coverage in the budgetary decision, and other progressives had originally pushed for a budget of $ 6 trillion. Biden had suggested less than $ 5 trillion.

Moderate Senator Joe Manchin, DW.V., expressed a very different opinion on Tuesday, telling reporters, “I think everything should be paid for. We have spent enough free money. “

In a statement Wednesday morning, Manchin said he was looking forward to reviewing the Senate Budget Committee’s agreement.

“I’m also very interested in how this proposal is paid for and how we can use it to remain globally competitive,” he said. “I will reserve the right to make any final judgment until I have had the opportunity to thoroughly evaluate the proposal.”

The budget will reportedly be in line with Biden’s promise not to impose taxes on anyone earning less than $ 400,000 a year.

Sanders said Tuesday night the legislation shows that “wealthy and large corporations will begin to pay their fair share of taxes so we can protect working families in this country.”

Another progressive, Senator Elizabeth Warren, D-Mass., Told NBC News that she hoped Biden would reassure the caucus that he “will put all his energy into making this happen.”

Warren also said she wanted to hear from the President how her efforts will affect key policy areas “because of all of these aspects – childcare, climate, home and community care, child tax deduction, free community college – all of that.” it’s about how we build a future. “

The Senator added that she “will always push for the number to be increased, but for now it’s my job to say, ‘This is a lot of money'” “.

Categories
Health

15 States Attain a Deal With Purdue Pharma Over Opioids

At a press conference Thursday to announce the settlement, the Massachusetts, New York and Minnesota attorneys general pointedly noted that they had asked the Sacklers for years to admit guilt and apologize, but family members refused.

Government lawyers said that instead of spending years looking for more money to meet urgent needs created by the opioid epidemic, they agreed to step back in order to free funds faster.

New York Democrat Rep. Carolyn B. Maloney and California Democrat Mark DeSaulnier introduced a law they call the Sackler Act that would allow states to prosecute company owners in bankruptcy proceedings that the attorneys general are tracking down strongly support own statements. But even if Congress passed such a law, the attorneys general added, the Sacklers and Purdue would almost certainly have closed the case long ago and would have escaped the scope of the bill.

As such, Purdue will cease to exist as such and re-emerge as a new company that would manufacture limited quantities of OxyContin and overdose reversal drugs, according to the overall bankruptcy filing. It would be overseen by an appointed board of directors. The profits would feed payments to funds for distant plaintiffs that would primarily support drug treatment and prevention programs.

Lawyers involved in the negotiations underlined the importance of the public document archive, which can hardly be surpassed in its breadth and depth. Although Purdue has already produced 13 million documents during the litigation, it has now added 20 million more. The size of this one company’s documents rivals that uncovered by the entire tobacco industry, a coveted consequence of the Big Tobacco litigation some 20 years ago.

The Purdue documents will contain statements, emails, and letters that go back two decades. They are expected to reveal detailed details of Purdue’s behind-the-scenes contacts with federal investigators and Food and Drug Administration officials as the company fended off tougher penalties for promoting turbo sales that touted OxyContin as effective and non-addictive. Experts assume that the considerations and mandates of Dr. Richard Sackler, a former President and CEO of Purdue.

In Thursday’s briefing, Maura Healey, the Massachusetts attorney general who was the first to suing Sacklers, said the document pool served as a promise to the families of opioid victims. “It will tell the whole story, all of the conversations, all of the discussions, all of the planning, all of the ways they make money and evade accountability and regulation,” she said.

Categories
World News

The Tech Chilly Warfare’s ‘Most Difficult Machine’ That’s Out of China’s Attain

SAN FRANCISCO — President Biden and many lawmakers in Washington are worried these days about computer chips and China’s ambitions with the foundational technology.

But a massive machine sold by a Dutch company has emerged as a key lever for policymakers — and illustrates how any country’s hopes of building a completely self-sufficient supply chain in semiconductor technology are unrealistic.

The machine is made by ASML Holding, based in Veldhoven. Its system uses a different kind of light to define ultrasmall circuitry on chips, packing more performance into the small slices of silicon. The tool, which took decades to develop and was introduced for high-volume manufacturing in 2017, costs more than $150 million. Shipping it to customers requires 40 shipping containers, 20 trucks and three Boeing 747s.

The complex machine is widely acknowledged as necessary for making the most advanced chips, an ability with geopolitical implications. The Trump administration successfully lobbied the Dutch government to block shipments of such a machine to China in 2019, and the Biden administration has shown no signs of reversing that stance.

Manufacturers can’t produce leading-edge chips without the system, and “it is only made by the Dutch firm ASML,” said Will Hunt, a research analyst at Georgetown University’s Center for Security and Emerging Technology, which has concluded that it would take China at least a decade to build its own similar equipment. “From China’s perspective, that is a frustrating thing.”

ASML’s machine has effectively turned into a choke point in the supply chain for chips, which act as the brains of computers and other digital devices. The tool’s three-continent development and production — using expertise and parts from Japan, the United States and Germany — is also a reminder of just how global that supply chain is, providing a reality check for any country that wants to leap ahead in semiconductors by itself.

That includes not only China but the United States, where Congress is debating plans to spend more than $50 billion to reduce reliance on foreign chip manufacturers. Many branches of the federal government, particularly the Pentagon, have been worried about the U.S. dependence on Taiwan’s leading chip manufacturer and the island’s proximity to China.

A study this spring by Boston Consulting Group and the Semiconductor Industry Association estimated that creating a self-sufficient chip supply chain would take at least $1 trillion and sharply increase prices for chips and products made with them.

That goal is “completely unrealistic” for anybody, said Willy Shih, a management professor at Harvard Business School who studies supply chains. ASML’s technology “is a great example of why you have global trade.”

The situation underscores the crucial role played by ASML, a once obscure company whose market value now exceeds $285 billion. It is “the most important company you never heard of,” said C.J. Muse, an analyst at Evercore ISI.

Created in 1984 by the electronics giant Philips and another toolmaker, Advanced Semiconductor Materials International, ASML became an independent company and by far the biggest supplier of chip-manufacturing equipment that involves a process called lithography.

Using lithography, manufacturers repeatedly project patterns of chip circuitry onto silicon wafers. The more tiny transistors and other components that can be added to an individual chip, the more powerful it becomes and the more data it can store. The pace of that miniaturization is known as Moore’s Law, named after Gordon Moore, a co-founder of the chip giant Intel.

In 1997, ASML began studying a shift to using extreme ultraviolet, or EUV, light. Such light has ultrasmall wavelengths that can create much tinier circuitry than is possible with conventional lithography. The company later decided to make machines based on the technology, an effort that has cost $8 billion since the late 1990s.

The development process quickly went global. ASML now assembles the advanced machines using mirrors from Germany and hardware developed in San Diego that generates light by blasting tin droplets with a laser. Key chemicals and components come from Japan.

Peter Wennink, ASML’s chief executive, said a lack of money in the company’s early years had led it to integrate inventions from specialty suppliers, creating what he calls a “collaborative knowledge network” that innovates quickly.

“We were forced to not do ourselves what other people do better,” he said.

ASML built on other international cooperation. In the early 1980s, researchers in the United States, Japan and Europe began considering the radical shift in light sources. The concept was taken up by a consortium that included Intel and two other U.S. chip makers, as well as Department of Energy labs.

ASML joined in 1999 after more than a year of negotiations, said Martin van den Brink, ASML’s president and chief technology officer. Other partners of the company included the Imec research center in Belgium and another U.S. consortium, Sematech. ASML later attracted big investments from Intel, Samsung Electronics and Taiwan Semiconductor Manufacturing Company to help fund development.

That development was made trickier by the quirks of extreme ultraviolet light. Lithography machines usually focus light through lenses to project circuit patterns on wafers. But the small EUV wavelengths are absorbed by glass, so lenses won’t work. Mirrors, another common tool to direct light, have the same problem. That meant the new lithography required mirrors with complex coatings that combined to better reflect the small wavelengths.

So ASML turned to Zeiss Group, a 175-year-old German optics company and longtime partner. Its contributions included a two-ton projection system to handle extreme ultraviolet light, with six specially shaped mirrors that are ground, polished and coated over several months in an elaborate robotic process that uses ion beams to remove defects.

Generating sufficient light to project images quickly also caused delays, Mr. van den Brink said. But Cymer, a San Diego company that ASML bought in 2013, eventually improved a system that directs pulses from a high-powered laser to hit droplets of tin 50,000 times a second — once to flatten them and a second time to vaporize them — to create intense light.

The new system also required redesigned components called photomasks, which act like stencils in projecting circuit designs, as well as new chemicals deposited on wafers that generate those images when exposed to light. Japanese companies now supply most of those products.

Since ASML introduced its commercial EUV model in 2017, customers have bought about 100 of them. Buyers include Samsung and TSMC, the biggest service producing chips designed by other companies. TSMC uses the tool to make the processors designed by Apple for its latest iPhones. Intel and IBM have said EUV is crucial to their plans.

“It’s definitely the most complicated machine humans have built,” said Darío Gil, a senior vice president at IBM.

Dutch restrictions on exporting such machines to China, which have been enforced since 2019, haven’t had much financial impact on ASML since it has a backlog of orders from other countries. But about 15 percent of the company’s sales come from selling older systems in China.

In a final report to Congress and Mr. Biden in March, the National Security Commission on Artificial Intelligence proposed extending export controls to some other advanced ASML machines as well. The group, funded by Congress, seeks to limit artificial intelligence advances with military applications.

Mr. Hunt and other policy experts argued that since China was already using those machines, blocking additional sales would hurt ASML without much strategic benefit. So does the company.

“I hope common sense will prevail,” Mr. van den Brink said.

Categories
Health

CRISPR gene enhancing may attain sufferers ‘very quickly’: Intellia CEO

Following a breakthrough trial where gene-editing technology CRISPR completed its first systematic delivery as medicine to a human body, Intellia Therapeutics CEO John Leonard said he hopes the gene therapy could be made available to patients “very, very soon.”

“These approaches are subjected to the standard sorts of clinical trials that any drug or gene therapy would be studied under, so we’re in the earlier stages of that,” Leonard said on CNBC’s “Closing Bell” on Thursday afternoon.

He added that over the next few years, the company expect the medical technology to be subjected to standard reviews, “but our hope is that this will be available to patients very, very soon.”

CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.

The latest development, the result of a trial between Intellia and biotech company Regeneron, treated a rare disease after being given as an IV infusion. Previously, other applications of the CRISPR technology had been limited to ex vivo therapy, or where cells are removed from the body for genetic manipulation in a laboratory and then reintroduced to the body.

“What’s particularly exciting about that is we were able to completely inactivate that gene and see that in the clinical effects of the patient, so a major advance in the gene editing space,” Leonard said.

Heart, diabetes and broad disease implications

CRISPR has broad applications, and Leonard said there is a lot of work being done to target some of the most common diseases and causes of death, such as heart disease and diabetes.

“The challenge is getting into those particular genes that cause disease, so we started in the liver, which is an area where there are many problems with disease-causing genes, and it’s been shown that we can reach that very, very successfully,” Leonard said. “There’s other tissues after that that we’re pursuing, especially the bone marrow, where a long list of blood-borne-type diseases can be addressed.”

A key for CRISPR is targeting diseases that are monogenic, or caused by one particular gene, allowing this type of gene-editing therapy to be successful, Leonard said. Other diseases that are polygenic, such a cancers or autoimmune diseases, will be “more difficult to tackle,” he added.

A researcher watches the CRISPR/Cas9 process through a stereomicroscope at the Max-Delbrueck-Centre for Molecular Medicine.

picture alliance | picture alliance | Getty Images

The new treatment is still in the early stages and it has not been priced yet, but as it develops, Leonard said he believes it will be “very valuable for patients and probably resource sparing for the health care system overall.”

“It really comes down to the some of the advantages with single application where literally it’s a one-and-done therapy,” Leonard said. “We expect over time this will be generally very, very favorable in the economics of this entire field.”

Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told the CNBC Evolve Global Summit that cost is a significant challenge, and in the case of sickle cell anemia, where CRISPR has had early success, treatment can still be $2 million.

“That is clearly not a price point that will make this available to most people that can benefit from it,” she said. Innovations in delivery of CRISPR may help lower cost, but Doudna also said that the medical field needs to figure out how to “scale the molecule production so that we reduce costs.”

She told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, “One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”

“It’s largely because the technology comes at a moment when there’s enormous demand for genome editing, as well as a lot of knowledge about genomes,” Doudna said.

Categories
Politics

Biden unable to succeed in settlement with Turkey’s Erdogan over Russian S-400

Russian S-400 missile battalions participate in tactical training to counter attacks of potential sabotage and reconnaissance groups. 

Vitaly Nevar | TASS via Getty Images

WASHINGTON – The Biden administration was unable to work out a resolution with Turkey following Ankara’s defiant purchase of a Russian weapons system, which the NATO alliance views as a security risk.

National security advisor Jake Sullivan told reporters Thursday on a call that President Joe Biden and Turkish President Recep Tayyip Erdogan discussed the 2017 multibillion-dollar weapons deal with Russia this week at NATO’s headquarters.

In December, the Trump administration slapped sanctions on Turkey, a NATO member, for buying the S-400 missile system in a confrontation not typically seen within the alliance.

“On the S-400, they discussed it. There was not a resolution of the issue. There was a commitment to continue the dialogue on the S-400,” Sullivan said, adding the Biden administration would have more to say on the matter after Washington and Ankara hold additional talks.

Turkish President Recep Tayyip Erdogan (L) and US President Joe Biden (R) hold a meeting at the NATO summit at the North Atlantic Treaty Organization (NATO) headquarters in Brussels, on June 14, 2021.

Murat Cetinmuhurdar | Anadolu Agency | Getty Images

During a NATO news conference, Erdogan said he had not changed his position on the S-400 despite having a “sincere” meeting with Biden.

Biden also said the meeting with Erdogan was productive, adding he was confident the U.S. will “make real progress with Turkey.”

Erdogan said Thursday that he told Biden to “not expect Turkey to take a different step on the F-35 and S-400 issues,” according to a report from Turkey’s state media.

“We must monitor developments closely. We will be following up on all our rights,” he said. “In the next period, our foreign ministers, defense ministers and defense industry chairs will be moving this process forward by meeting with their counterparts,” Erdogan added.

In multiple efforts to deter Turkey from buying Russia’s S-400 missile system, the State Department offered in 2013 and 2017 to sell the country Raytheon’s Patriot missile system. Ankara passed on the Patriot both times because the U.S. declined to provide a transfer of the system’s sensitive missile technology.

A F-35 fighter jet is seen as Turkey takes delivery of its first F-35 fighter jet with a ceremony at the Lockheed Martin in Forth Worth, Texas, United States on June 21, 2018.

Atilgan Ozdil | Anadolu Agency | Getty Images

Under the Countering America’s Adversaries Through Sanctions Act any foreign government working with the Russian defense sector will find itself in the crosshairs of U.S. economic sanctions.

Despite warnings from the United States and other NATO allies, Turkey accepted the first of four S-400 missile batteries from the Kremlin in July 2019.

A week later, the U.S. cut Turkey, a financial and manufacturing partner, from the F-35 program.

Due to Turkey’s removal from the F-35 program, U.S. defense giant Lockheed Martin offered the jets originally slated to join Ankara’s arsenal to other customers.

Correction: Erdogan said Thursday that he told Biden to “not expect Turkey to take a different step on the F-35 and S-400 issues,” according to a report from Turkey’s state media. An earlier version misstated the day.

Categories
World News

G7 nations attain historic deal on world tax reform

British Chancellor of the Exchequer Rishi Sunak (from left), US Treasury Secretary Janet Yellen, IMF Managing Director Kristalina Georgieva and Canada’s Treasury Secretary Chrystia Freeland chatting on the first day of the Seven Treasury Ministers’ meeting at Lancaster House in London on June 4, 2021.

Stefan Rousseau | AFP | Getty Images

LONDON – Treasury ministers of the most advanced economies, known as the Group of Seven, have backed a US proposal requiring companies around the world to pay at least 15% corporate income tax.

“Today, after years of discussion, the finance ministers of the G-7 reached a historic agreement to reform the global tax system, make it fit for the global digital age – and above all to ensure that it is fair to the right companies paying the right taxes in the right places, “said UK Treasury Secretary Rishi Sunak in a video statement on Saturday.

When completed, it would represent a major development in global taxation. The G-7 members, which include Canada, France, Germany, Italy, Japan, the UK and the US, will meet for a summit next week in Cornwall, UK.

“We are committed to finding an equitable solution to the allocation of tax rights, with market countries being granted tax rights on at least 20% of profits that exceed a 10% margin for the largest and most profitable multinational corporations,” said one Statement by the G -7 finance ministers.

“We will ensure adequate coordination between the application of the new international tax rules and the elimination of all taxes on digital services and other relevant similar measures for all businesses,” it said.

US Treasury Secretary Janet Yellen, who is in London for the face-to-face meeting, hailed the move as significant and unprecedented.

“This global minimum tax would end the race to the bottom in corporate taxation and ensure fairness for the middle class and working population in the US and around the world,” she tweeted.

President Joe Biden and his administration originally proposed a minimum global tax rate of 21% to end a race to the bottom between different countries in attracting international businesses. However, after tough negotiations, a compromise was reached to set the bar at 15%.

A global deal in this area would be good news for countries on budget struggling to rebuild their economies after the coronavirus crisis.

But Biden’s idea was not received with the same enthusiasm around the world. Britain, for example, did not immediately support the proposal.

US President Joe Biden speaks at a meeting with a bipartisan group of Congressmen.

Swimming pool | Getty Images News | Getty Images

The issue can also be controversial within the European Union, where different member states levy different corporate tax rates and thereby attract well-known companies. Ireland’s tax rate, for example, is 12.5%, while France’s can be up to 31%.

In an April speech, Irish Treasury Secretary Paschal Donohoe said smaller nations should have lower tax rates because they don’t have the same scalability as larger economies, the Guardian reported.

The world’s most powerful economies have been arguing over taxation for some time, especially amid plans to tax digital giants more heavily.

Under former President Donald Trump, the United States vehemently opposed digital tax initiatives in various countries and threatened to impose trade tariffs on countries that were planning to tax US technology companies.

Some large companies around the world responded positively to the agreement on Saturday. Nick Clegg, Facebook’s vice president of global affairs, tweeted that the company welcomed the G-7 tax regime.

“We want the international tax reform process to be successful, and we recognize that this could mean Facebook pays more taxes in other places,” Clegg wrote.

Google spokesman Jose Castaneda told CNBC in a statement that the company supports efforts to update international tax rules. “We hope that countries will continue to work together to ensure that a balanced and lasting deal is reached soon,” he said.

Categories
Health

70 % Covid Vaccination Fee Might Be in Attain, New Ballot Suggests

A new poll suggests the US may be on track to vaccinate at least 70 percent of the adult population against Covid-19 by the summer.

In the latest survey by the Kaiser Family Foundation, 62 percent of respondents said they had received at least one dose of vaccine, up from 56 percent in April. At the same time, around a third of those classified as “waiting” stated that they had already made vaccine appointments or that they would have planned to do so shortly.

Dr. William Schaffner, National Infectious Disease Foundation medical director and vaccine expert, found the results encouraging.

“I think there are many people on the fence worried about things moving too fast and possible side effects. However, those concerns will be allayed as more friends and acquaintances celebrate the vaccination,” said Dr. Schaffner, who did not participate in the monthly survey, the Covid-19 Vaccine Monitor.

“You get a growing sense of comfort and security that ‘people like me’ will be vaccinated,” which he said was essential in building confidence in the vaccines.

The two populations that saw the largest increases in vaccination rates from April to May were Latino adults (from 47 percent to 57 percent) and adults without a college degree (from 48 percent to 55 percent).

The telephone survey of 1,526 adults was conducted in English and Spanish from May 18-25.

On May 10, the Food and Drug Administration approved Pfizer and BioNTech’s vaccine for children 12 years and older. The survey found that 40 percent of parents said either their child has already received at least one dose or will soon receive one.

However, the parents of younger children were much more cautious. Only about a quarter expressed willingness to have their children vaccinated once the shots have been approved for them.

The results suggest that efforts to protect as many young students as possible from Covid-19 at the start of the school year may face obstacles.

While public health experts welcomed the continued improvement in vaccination rates, they found that the pool of most willing adults was shrinking.

“There is almost no low hanging fruit at this point, but there is a path to a slow but steady increase in vaccination rates through improved access, information, advocacy and incentives,” said Drew Altman, president and chief executive officer of Kaiser Family Foundation.

President Biden’s goal is to achieve 70 percent adult vaccine coverage by July 4th. Dr. Schaffner said he thought the goal was possible. “We have to work harder,” he said.

The survey authors said the target was realistic because in addition to 62 percent of adults who received at least one dose, another 4 percent said they wanted the shot as soon as possible and another 4 percent – a third of the ” “wait and see” group said they had made an appointment or intend to do so within three months.

Despite the positive news, vaccination rates in adults who previously reported significant hesitation (7 percent) or outright rejection (13 percent) have remained unchanged for several months. And a third of the “wait and see” group said they would wait at least a year before taking the picture.

The survey also looked at attitudes towards vaccination incentives and the impact of government news about the shots. Financial incentives, such as the million dollar lottery in Ohio for the newly vaccinated, are being pushed back a little.

However, the survey found that such rewards can be successful motivators for people to get the shots. Fifteen percent of non-vaccinated adults in the survey said their state’s offer of $ 100 may make them reconsider, as well as free transportation and tickets to a sporting event or concert.

Earlier this month, people vaccinated at an event at Talladega Superspeedway in Alabama were able to complete two winning laps on the track. (Cars and trucks, yes; motorcycles, no.) Similar incentives are being offered across the country.

About 20 percent of unvaccinated workers said they would be more likely to get the shots if their employer gave them paid time off for the dates and time needed to recover from side effects.

The report also showed that the public had some confidence in the government’s health-related messages, although many were confused by the Centers for Disease Control and Prevention’s announcement earlier this month that vaccinated people could largely avoid face masks and social distancing. Over half said the CDC’s guidelines were generally clear and accessible, but about 40 percent found them confusing and cloudy.

Notably, 85 percent of people who were not vaccinated said that the CDC’s new guidelines no longer made them ready to be vaccinated.

But another cohort viewed government approval as a potential launch vehicle. The survey found that a third of unvaccinated adults, including 44 percent in the “wait and see” group, said they would be more likely to receive a vaccine once it received full approval from the Food and Drug Administration. Vaccine makers Moderna and Pfizer-BioNTech recently announced that they are making progress towards this goal.